Home » Stocks » KALA

Kala Pharmaceuticals, Inc. (KALA)

Stock Price: $6.44 USD 0.16 (2.55%)
Updated Oct 28, 2020 9:51 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 361.03M
Revenue (ttm) 4.54M
Net Income (ttm) -90.40M
Shares Out 56.06M
EPS (ttm) -2.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $6.44
Previous Close $6.28
Change ($) 0.16
Change (%) 2.55%
Day's Open 6.80
Day's Range 6.41 - 7.00
Day's Volume 1,645,708
52-Week Range 3.45 - 14.68

More Stats

Market Cap 361.03M
Enterprise Value 264.93M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 56.06M
Float 48.42M
EPS (basic) -2.27
EPS (diluted) -2.18
FCF / Share -1.46
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6.53M
Short Ratio 4.43
Short % of Float 13.48%
Beta 0.31
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 79.61
PB Ratio 3.37
Revenue 4.54M
Operating Income -83.17M
Net Income -90.40M
Free Cash Flow -81.57M
Net Cash 96.09M
Net Cash / Share 1.71
Gross Margin 89.66%
Operating Margin -1,833.94%
Profit Margin -1,993.40%
FCF Margin -1,798.57%
ROA -24.50%
ROE -95.15%
ROIC -58.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (7)

Buy 6
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$19.71*
(206.06% upside)
Low
10.0
Current: $6.44
High
39.0
Target: 19.71
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue6.07---0.05
Gross Profit4.07---0.05
Operating Income-88.22-64.72-39.88-32.67-15.95
Net Income-94.35-66.74-42.21-33.17-16.68
Shares Outstanding34.2126.7511.381.181.12
Earnings Per Share-2.76-2.49-3.71-28.07-14.89
Operating Cash Flow-92.72-54.12-34.10-27.35-15.09
Capital Expenditures-1.34-1.58-0.48-0.15-0.25
Free Cash Flow-94.06-55.70-34.58-27.50-15.34
Cash & Equivalents98.0318311545.585.87
Total Debt10199.4418.659.659.80
Net Cash / Debt-3.1583.6696.0535.93-3.93
Assets15422111746.338.45
Liabilities12511626.8715.7014.24
Book Value29.6910589.68-87.76-56.66
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Kala Pharmaceuticals, Inc.
Country United States
Employees 136
CEO Mark T. Iwicki

Stock Information

Ticker Symbol KALA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: KALA
IPO Date July 20, 2017

Description

Kala Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts.